• Publications
  • Influence
Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens.
Little is known about the function of human cancer/testis antigens (CTAs), such as MAGE, BAGE, GAGE, HOM-MEL-40, and NY-ESO-1, the expression of which is restricted to human malignancies and testis.Expand
  • 269
  • 17
  • PDF
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.
Pharmacokinetics of 8 doses of rituximab (375 mg/m(2)) given in combination with 2-week cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone/prednisolone (CHOP-14) was determined byExpand
  • 179
  • 11
  • PDF
Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.
PURPOSE R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard care for aggressive B-cell lymphoma. A prospective trial was conducted to investigate the roleExpand
  • 152
  • 10
  • PDF
Expression of SSX genes in human tumors
The HOM‐MEL‐40 antigen which is encoded by the SSX‐2 gene was originally detected as a tumor antigen recognized by autologous IgG antibodies in a melanoma patient. Expression analysis demonstratedExpand
  • 180
  • 8
Analysis of the B‐cell repertoire against antigens expressed by human neoplasms
Summary: The screening of tumor‐derived expression libraries for antigens detected by high‐titer immunoglobulin G antibodies from the sera of patients with cancer by SEREX (serological identificationExpand
  • 116
  • 6
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study
PURPOSE To study pharmacokinetics, toxicity, and efficacy of prolonged rituximab exposure in elderly patients with diffuse large B-cell lymphoma (DLBCL). PATIENTS AND METHODS In theExpand
  • 66
  • 4
  • PDF
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.
PURPOSE To study clinical presentation, outcome, and the role of radiotherapy in patients with aggressive B-cell lymphoma and skeletal involvement treated with and without rituximab. PATIENTS ANDExpand
  • 64
  • 4
Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.
BACKGROUND To improve outcome of elderly patients with diffuse large B-cell lymphoma, dose-dense rituximab was evaluated in the prospective DENSE-R-CHOP-14 trial. PATIENTS AND METHODS RituximabExpand
  • 47
  • 4
Expression of cancer testis genes in human brain tumors.
Cancer-testis (CT) genes are expressed in a variety of human cancers but not in normal tissues, except for testis tissue, and represent promising targets for immunotherapeutic and gene therapeuticExpand
  • 117
  • 3
  • PDF
Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens.
The screening of tumor-derived expression libraries for antigens which are recognized by high titered IgG antibodies present in autologous sera of the cancer patients by SEREX (serologicalExpand
  • 50
  • 2